Repeated vaccination of cows with HIV env gp140 during subsequent pregnancies elicits and sustains an enduring strong env-binding and neutralising antibody response

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Heydarchi, Behnaz ^a   Center, Rob J ^a   Gonelli, Christopher ^a   Muller, Brian ^a   Mackenzie, Charlene ^a   Khoury, Georges ^a   Lichtfuss, Marit ^a   Rawlin, Grant ^a   Purcell, Damian F J ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; COW; DRUG POTENCY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; IC80; INHIBITORY CONCENTRATION; NONHUMAN; PREGNANCY; REVACCINATION; TREATMENT DURATION; VIRUS NEUTRALIZATION; ANIMAL; BOVINE; COLOSTRUM; HELA CELL LINE; HIV INFECTIONS; HUMAN; IMMUNOLOGY; VACCINATION; VIROLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; CATTLE; COLOSTRUM; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HELA CELLS; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; PREGNANCY; VACCINATION;

EID: 84976407792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157353     Document Type: Article

References (49)

1. Marrazzo J.M., et al., Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med, 2015. 372(6): p. 509-18. doi: 10.1056/NEJMoa1402269 PMID: 25651245
2. Celum C. and Baeten J.M., Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis, 2012. 25(1): p. 51-7. doi: 10.1097/QCO.0b013e32834ef5ef PMID: 22156901
3. Van Damme L., et al., Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet, 2002. 360(9338): p. 971-7. PMID: 12383665
4. Hillier S.L., et al., In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr, 2005. 39 (1): p. 1-8. PMID: 15851907
5. Mayer K.H., et al., Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis, 2001. 32(3): p. 476-82. PMID: 11170957
6. Ramjee G., Kamali A., and McCormack S., The last decade of microbicide clinical trials in Africa: from hypothesis to facts. AIDS, 2010. 24 Suppl 4: p. S40-9. doi: 10.1097/01.aids.0000390706.81383.f3 PMID: 21042052
7. Abdool Karim, Q., et al., Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010. 329(5996): p. 1168-74. doi: 10.1126/science.1193748 PMID: 20643915
8. Kramski M., et al., Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides. Antimicrob Agents Chemother, 2012. 56(8): p. 4310-9. doi: 10.1128/AAC.00453-12 PMID: 22664963
9. Bures R., et al., Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses, 2000. 16(18): p. 2019-35. PMID: 11153085
10. BeddowsS.et al.Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individualsJ Virol19997321740-1745PMID: 9882391
11. Bunnik E.M., et al., Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med, 2010. 16(9): p. 995-7. doi: 10.1038/nm.2203 PMID: 20802498
12. Tomaras G.D. and Haynes B.F., HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS, 2009. 4(5): p. 373-9. doi: 10.1097/COH.0b013e32832f00c0 PMID: 20048700
13. McCoy L.E., et al., Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med, 2012. 209(6): p. 1091-103. doi: 10.1084/jem.20112655 PMID: 22641382
14. Kramski M., et al., Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. Eur J Immunol, 2012. 42(10): p. 2771-81. doi: 10.1002/eji.201242469 PMID: 22730083
15. Center R.J., et al., Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine, 2009. 27(47): p. 6605-12. doi: 10.1016/j.vaccine.2009.08.016 PMID: 19712773
16. Wu X., et al., Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science, 2010. 329(5993): p. 856-61. doi: 10.1126/science.1187659 PMID: 20616233
17. Lynch R.M., et al., The development of CD4 binding site antibodies during HIV-1 infection. J Virol, 2012. 86(14): p. 7588-95. doi: 10.1128/JVI.00734-12 PMID: 22573869
18. Goo L., et al., Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope. J Virol, 2012. 86(18): p. 9566-82. doi: 10.1128/JVI. 00953-12 PMID: 22740394
19. Haigwood N.L., et al., Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses, 1990. 6(7): p. 855-69. PMID: 2390335
20. Earl P.L., et al., Isolate- and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. AIDS Res Hum Retroviruses, 1989. 5(1): p. 23-32. PMID: 2541747
21. Doria-Rose N.A., et al., Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol, 2010. 84(3): p. 1631-6. doi: 10.1128/ JVI.01482-09 PMID: 19923174
22. Gray E.S., et al., Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol, 2009. 83(17): p. 8925-37. doi: 10.1128/JVI.00758-09 PMID: 19553335
23. Doria-Rose N.A., et al., Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol, 2009. 83(1): p. 188-99. doi: 10. 1128/JVI.01583-08 PMID: 18922865
24. Binley J.M., et al., Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol, 2008. 82(23): p. 11651-68. doi: 10.1128/JVI.01762-08 PMID: 18815292
25. Mahalanabis M., et al., Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol, 2009. 83(2): p. 662-72. doi: 10.1128/ JVI.01328-08 PMID: 18987151
26. Rademeyer C., et al., Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology, 2007. 368(1): p. 172-81. PMID: 17632196
27. Moore P.L., et al., Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol, 2006. 80(5): p. 2515-28. PMID: 16474158
28. Poignard P., et al., Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol, 2003. 77(1): p. 353-65. PMID: 12477840
29. Doria-Rose N.A., et al., Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014. 509(7498): p. 55-62. doi: 10.1038/nature13036 PMID: 24590074
30. Klein F., et al., Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med, 2012. 209(8): p. 1469-79. doi: 10.1084/jem.20120423 PMID: 22826297
31. Walker L.M., et al., Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science, 2009. 326(5950): p. 285-9. doi: 10.1126/science.1178746 PMID: 19729618
32. Kovacs J.M., et al., HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A, 2012. 109(30): p. 12111-6. doi: 10.1073/pnas.1204533109 PMID: 22773820
33. Zhang P.F., et al., Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A, 2007. 104(24): p. 10193-8. PMID: 17540729
34. Hammonds J., et al., Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol, 2005. 79(23): p. 14804-14. PMID: 16282480
35. Bower J.F., et al., Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol, 2004. 78(9): p. 4710-9. PMID: 15078953
36. Yang X., et al., Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol, 2002. 76(9): p. 4634-42. PMID: 11932429
37. Rerks-Ngarm S., et al., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009. 361(23): p. 2209-20. doi: 10.1056/NEJMoa0908492 PMID: 19843557
38. Haynes B.F., et al., Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med, 2012. 366(14): p. 1275-86. doi: 10.1056/NEJMoa1113425 PMID: 22475592
39. Liao H.X., et al., Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity, 2013. 38(1): p. 176-86. doi: 10.1016/j.immuni.2012.11.011 PMID: 23313589
40. Pancera M., et al., Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 2014. 514(7523): p. 455-61. doi: 10.1038/nature13808 PMID: 25296255
41. Yasmeen A., et al., Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology, 2014. 11: p. 41. doi: 10.1186/1742-4690-11-41 PMID: 24884783
42. Julien J.P., et al., Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science, 2013. 342 (6165): p. 1477-83. doi: 10.1126/science.1245625 PMID: 24179159
43. Ringe R.P., et al., Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A, 2013. 110(45): p. 18256-61. doi: 10.1073/ pnas.1314351110 PMID: 24145402
44. Williams W.B., et al., HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015. 349((6249).
45. Zhao Y., Jackson S.M., and Aitken R., The bovine antibody repertoire. Dev Comp Immunol, 2006. 30 (1-2): p. 175-86. PMID: 16054212
46. Sinclair M.C., Gilchrist J., and Aitken R., Bovine IgG repertoire is dominated by a single diversified VH gene family. J Immunol, 1997. 159(8): p. 3883-9. PMID: 9378976
47. Zhou T., et al., Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature, 2007. 445(7129): p. 732-7. PMID: 17301785
48. Collis A.V., Brouwer A.P., and Martin A.C., Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol, 2003. 325(2): p. 337-54. PMID: 12488099
49. Kaushik A.K., et al., Somatic hypermutations and isotype restricted exceptionally long CDR3H contribute to antibody diversification in cattle. Vet Immunol Immunopathol, 2009. 127(1-2): p. 106-13. doi: 10.1016/j.vetimm.2008.09.024 PMID: 19012969